BAFF blockade may be less effective in diseases driven by IgA1 autoantibodies, and indeed, there are no reports in the literature of belimumab’s efficacy in IgA nephropathy, which is thought to be principally associated with IgA1 autoantibodies.21 This evidence concerns the gene TNFSF13B and IgA glomerulonephritis.